Abstract
Objective To investigate the protective effects of breviscapine in renal injury caused by extracorporeal shock wave therapy for renal calculi. Methods Totally 120 patients with renal calculi treated in our hospital from January 2015 to January 2017 were selected and randomly divided into the control group and the study group with 60 cases in each group. The patients in the control group were treated with extracorporeal shock wave, and patients in the study group were treated with breviscapine assisted extracorporeal shock wave. Serum related factors [serum endothelin 1 (ET-1), malondialdehyde (MDA), kidney injury molecule-1 (Kim-1)], biochemical parameters of renal injury [blood urea nitrogen (BUN), β2 microglobulin (β2-MG), urinary N-acetyl β-D glucosaminidase (NAG)], clinical curative effect and prognosis [the World Health Organization Quality of Life Scale (WHOQOL-BRFE) score] were observed before and after treatment. Results There were no significant differences in ET-1, MDA, Kim-1, BUN, β2-MG, NAG and WHOQOL-BRFE scores between the two groups before treatment (P>0.05). After treatment, ET-1, MDA, BUN and WHOQOL-BRFE scores were significantly higher, and Kim-1, β2-MG and NAG were significantly lower than those before treatment, and the changes in the study group were more obvious than those in the control group (P<0.05). After treatment, the total effective rate of the study group was [90.00%(54/60)] was higher than that of the control group [75.00%(45/60)] (P<0.05). Conclusions Breviscapine adjuvant therapy is significantly effective in the treatment of patients with renal injury caused by extracorporeal shock wave therapy for renal calculi. It can improve the clinical curative effect, the prognosis and quality of life through effective regulation of related factors in serum biochemical indexes of renal injury. Key words: Kidney Calculi; ERIGERON BREVISCAPUS; Kidney; High-Energy Shock Waves
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
